Position
Chief Executive Officer
Company
Jubilant Therapeutics
YardleyManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Jubilant Pharmova Limited has appointed Daniel J. O’Connor as the new Chief Executive Officer of its proprietary novel drugs business, Jubilant Therapeutics Inc. This leadership transition is aimed at accelerating the company's innovation-led growth strategy in the biotech and oncology space.
Quick answer
Jubilant Pharmova Appoints Daniel J. O’Connor as Chief Executive Officer (December 2, 2025). Jubilant Therapeutics is based in Yardley, Pennsylvania, United States.
- Who is the new Chief Executive Officer at Jubilant Therapeutics?
- Jubilant Therapeutics named Daniel J. O’Connor Chief Executive Officer, announced December 2, 2025.
- What did Jubilant Therapeutics announce on December 2, 2025?
- Jubilant Pharmova Limited has appointed Daniel J. O’Connor as the new Chief Executive Officer of its proprietary novel drugs business, Jubilant Therapeutics Inc. This leadership transition is aimed at accelerating the company's innovation-led growth strategy in the biotech and oncology space.
- What does Jubilant Therapeutics do?
- Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases.
- Where is Jubilant Therapeutics based?
- Jubilant Therapeutics is based in Yardley, Pennsylvania, United States.
- Which similar companies made leadership changes around the same time?
- VistaGen (December 1, 2025), Centessa Pharmaceuticals plc (December 12, 2025), Kalaris Therapeutics (November 3, 2025) and Mezzion Pharma (January 6, 2026) also announced leadership changes within 45 days of Jubilant Therapeutics.
Source: Fundz verified event record.
Other recent leadership changes in Therapeutics and Pharmaceutical
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Vistagen Appoints Nick Tressler as Chief Financial Officer (December 1, 2025)
- Centessa Pharmaceuticals Appoints Mario Alberto Accardi as CEO (December 12, 2025)
- Kalaris Therapeutics Appoints Matthew Gall as Chief Financial Officer (November 3, 2025)
- Mezzion Pharmaceuticals Appoints Ridwan Shabsigh as President and COO (January 6, 2026)
- Sudo Biosciences Appoints Paul Bavier as Chief Legal Officer (December 4, 2025)
- GridAI Technologies Corp. Appoints Marshall Chapin as Chief Executive Officer (December 4, 2025)
Who to call at Jubilant Therapeutics, and when
A new leader at Jubilant Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Jubilant Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Jubilant Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Jubilant Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Jubilant Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Jubilant Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.